Erythromycin Ethylsuccinate Capsules

This product belongs to the macrolide antibiotics, which is the ethyl succinate of erythromycin. It is more stable than erythromycin in gastric acid. This product is an antibacterial agent, but it also has a bactericidal effect on certain bacteria at high concentrations. It has antibacterial activity against Staphylococcus (including enzyme-producing strains), various groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, certain spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

The main ingredient of this product is erythromycin ethylsuccinate.

The contents of this product are white granules or powder.

1. This product is used to treat the following infections in patients who are allergic or resistant to penicillin β-lactams: acute tonsillitis, acute pharyngitis, sinusitis caused by hemolytic streptococci, pneumococcus, etc.; scarlet fever and cellulitis caused by hemolytic streptococci; diphtheria and diphtheria carriers; gas gangrene, anthrax, tetanus; actinomycosis; syphilis; listeriosis, etc. 2. Mycoplasma pneumonia. 3. Chlamydia pneumoniae pneumonia. 4. Urinary and reproductive system infections caused by Chlamydia and Mycoplasma. 5. Chlamydia trachomatis conjunctivitis. 6. Oral infections caused by anaerobic bacteria. 7. Campylobacter jejuni enteritis. 8. Whooping cough. 9. Legionnaires' disease. 10. Recurrence of rheumatic fever, infective endocarditis (after rheumatic heart disease, congenital heart disease, heart valve replacement surgery) and oral and upper respiratory tract medical treatment

Oral administration: 1.6g per day for adults, divided into 2 to 4 times. For patients with Legionnaires' disease, 0.4 to 1.0g per time, 4 times a day. The daily dose for adults should generally not exceed 4g. To prevent streptococcal infection, 400mg per time, twice a day. For chlamydia or Ureaplasma urealyticum infection, 800mg per time, once every 8 hours, for 7 days; or 400mg per time, once every 6 hours, for 14 days. For children, 7.5 to 12.5mg/kg per time, 4 times a day; or 15 to 25mg/kg per time, 2 times a day; in case of severe infection, the daily dose can be doubled and taken in 4 times. For children with pertussis, 10 to 12.5mg/kg per time, 4 times a day, for a course of 14 days.

1. Patients with hepatotoxic reactions after taking this product are more common than those taking other erythromycin preparations. After taking the drug for several days or 1 to 2 weeks, patients may experience fatigue, nausea, vomiting, abdominal pain, rash, fever, etc. Jaundice may sometimes occur, and liver function tests show cholestasis, which can often be recovered after stopping the drug. 2. Gastrointestinal reactions include diarrhea, nausea, vomiting, upper abdominal pain, mouth and tongue pain, and decreased appetite, and their incidence is related to the dose. 3. When used in large doses (ge; 4g/day), especially in patients with liver and kidney diseases or elderly patients, hearing loss may occur, which is mainly related to excessive blood drug concentration (12mg/L), and most of them can be recovered after stopping the drug. 4. Allergic reactions are manifested as drug fever, rash, eosinophilia, etc., with an incidence of about 0.5% to 1%. 5. Others, occasionally arrhythmia, oral or vaginal candidal infection.

It is contraindicated for patients with severe liver damage or those who are allergic to this product.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Because the possibility of hepatotoxicity increases and this product can pass through the placenta, pregnant women should use it with caution. Because a considerable amount of this product enters breast milk, lactating women should use it with caution or stop breastfeeding. Precautions for the elderly: Not yet clear.

1. This product can inhibit the metabolism of antiepileptic drugs such as carbamazepine and valproic acid, resulting in increased blood concentrations and toxic reactions. Combination with alfentanil can inhibit the metabolism of the latter and prolong its duration of action. Combination with antihistamines such as astemizole or terfenadine can increase cardiac toxicity, and combination with cyclosporine can increase the latter's blood concentration and produce nephrotoxicity. 2. It has an antagonistic effect on chloramphenicol and lincomycin, and it is not recommended to use them at the same time. 3. This product is an antibacterial agent and can interfere with the bactericidal efficacy of penicillin. Therefore, when rapid bactericidal effects are required, such as the treatment of meningitis, the two should not be used at the same time. 4. Patients who take warfarin for a long time can prolong the prothrombin time when using this product, thereby increasing the risk of bleeding. Elderly patients should pay special attention. When the two must be used at the same time, the dose of warfarin should be appropriately adjusted and the prothrombin time should be closely observed. 5. Except for dihydroxypropylphylline, the simultaneous use of this product with xanthine drugs can reduce the hepatic clearance of aminophylline, leading to an increase in serum aminophylline concentration and (or) increased toxic reactions. This phenomenon is more likely to occur after 6 days of co-use, and the reduction in aminophylline clearance is proportional to the serum peak of this product. Therefore, the dose of xanthine drugs should be adjusted when and after the two are used together. 6. Combination with other hepatotoxic drugs may enhance hepatotoxicity. 7. Large doses of this product combined with ototoxic drugs, especially in patients with renal impairment, may increase ototoxicity. 8. When used in combination with lovastatin, it can inhibit its metabolism and increase blood concentration, which may cause rhabdomyolysis; when used in combination with midazolam or triazolam, it can reduce the clearance of the two and enhance their effects. 9. This product can obstruct the enterohepatic circulation of sex hormones, and combined with oral contraceptives can reduce their efficacy.

Keep away from light and store in sealed container.

0.125g (125,000 units) based on C37H67NO13

24 months.

Nanyang Tianheng Pharmaceutical FACTORY of Beijing Tianheng Pharmaceutical Institute

• Founded in:

  2002-03-25

• Address:

  East Section of South Ring Road, Dengzhou City, Henan Province

• Tax NO.:

  914113817374160007

• Registered Funds:

  3 million yuan

• Website:

  Log in to view

• Email:

  Log in to view